GFM
ACRS icon

GF Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

GF Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
2,553
+134
+6% +$598 ﹤0.01% 519
2026
Q1 		$9.07K Buy
2,419
+291
+14% +$982 ﹤0.01% 568
2025
Q4 		$6.41K Buy
+2,128
New +$5.38K ﹤0.01% 607

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

GF Fund Management's ACRS Position: Q2 2026 in Review

GF Fund Management increased its Aclaris Therapeutics (ACRS) stake by 5.5% in Q2 2026, buying an estimated $598 and bringing the position to 2,553 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #519.

GF Fund Management first reported a position in ACRS in Q4 2025 and has held it in 3 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • GF Fund Management held 2,553 shares of Aclaris Therapeutics worth $13.5K as of Q2 2026.
  • GF Fund Management bought 134 Aclaris Therapeutics shares in Q2 2026, an estimated $598.
  • Aclaris Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #519 holding.
  • GF Fund Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.